Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02405221 · ClinicalTrials.gov registry record · Phase 1
Safety and Feasibility of TA-CIN Vaccine in HPV16 Associated Cervical Cancer
A Phase 1 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT02405221 is a Phase 1 study that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 15 participants.
The verdict
NCT02405221, a Phase 1 study, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
This study will be looking at what dose of the TA-CIN vaccine is safe and effective in patients with a history of HPV16-associated cervical cancer.
Interventions
- BIOLOGICAL TA-CIN (arm)
- BIOLOGICAL TA-CIN (thigh)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2019-04-04 |
| Est. Completion | 2025-01-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02405221
The ClinicalTrials.gov registry entry for NCT02405221 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which TA-CIN (arm) is the first listed.
NCT02405221 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02405221 about?
NCT02405221 is a clinical study titled "Safety and Feasibility of TA-CIN Vaccine in HPV16 Associated Cervical Cancer". This study will be looking at what dose of the TA-CIN vaccine is safe and effective in patients with a history of HPV16-associated cervical cancer.
What is the current status of trial NCT02405221?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2019-04-04. Estimated completion is 2025-01-31.
What interventions are being tested in trial NCT02405221?
The interventions under investigation include: TA-CIN (arm) (BIOLOGICAL), TA-CIN (thigh) (BIOLOGICAL).
Who is sponsoring clinical trial NCT02405221?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.